

Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/T22085E9A2D4EN.html>

Date: December 2022

Pages: 114

Price: US\$ 3,500.00 (Single User License)

ID: T22085E9A2D4EN

Abstracts

Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni²⁺. It responses are triggered by Ni²⁺ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 40 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Allergic Rhinitis, Bacterial Sepsis, Coronavirus Disease

2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Lung Injury, Acute On Chronic Liver Failure (ACLF), Allergic Asthma, Alzheimer's Disease, Atherosclerosis, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Food Allergy, Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Kidney Disease (Nephropathy), Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Dermatological Disorders, Unspecified Infectious Diseases, Unspecified Rare Disease and Viral Respiratory Tract Infection.

The latest report Toll Like Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)

The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development

13therapeutics Inc

Acepre LLC

Akaza Bioscience Ltd

Allodynic Therapeutics LLC

Apollo Therapeutics LLC

AptaTargets SL

Ayuviz Research Inc

Celestial Therapeutics Inc

Douleur Therapeutics Inc

Edesa Biotech Inc

EyeGene Inc

FasCure Therapeutics LLC

Genesen Co Ltd

Immunovo BV (Inactive)

Inimmune Corp

Kupando GmbH

Lubris Biopharma

Merck & Co Inc

Pattern Pharma Inc

Protara Therapeutics Inc

Revelation Biosciences Inc

Soin Therapeutics LLC

TaiwanJ Pharmaceuticals Co Ltd
Vascular Biogenics Ltd
Xalud Therapeutics Inc
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
C-34 - Drug Profile
Product Description
Mechanism Of Action
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
CT-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ECF-843 - Drug Profile
Product Description
Mechanism Of Action

History of Events
G-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GS-200 - Drug Profile
Product Description
Mechanism Of Action
INI-2004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KUP-101 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
P-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
P-MAPA - Drug Profile
Product Description

Mechanism Of Action

History of Events

P2PAR-100 - Drug Profile

Product Description

Mechanism Of Action

paridiprubart - Drug Profile

Product Description

Mechanism Of Action

History of Events

PEPA-10 - Drug Profile

Product Description

Mechanism Of Action

History of Events

resatorvid - Drug Profile

Product Description

Mechanism Of Action

History of Events

REVTX-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

REVTx-99 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit TLR2 and TLR4 for Bacterial Sepsis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease,
Chronic Asthma and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease -
Drug Profile

Product Description

Mechanism Of Action

TARA-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TJC-0133 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VB-201 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VB-703 - Drug Profile

Product Description

Mechanism Of Action

History of Events

XT-203 - Drug Profile

Product Description

Mechanism Of Action

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by 13therapeutics Inc, 2022

Pipeline by Acepre LLC, 2022

Pipeline by Akaza Bioscience Ltd, 2022

Pipeline by Allodynic Therapeutics LLC, 2022

Pipeline by Apollo Therapeutics LLC, 2022

Pipeline by AptaTargets SL, 2022

Pipeline by Ayuvis Research Inc, 2022

Pipeline by Celestial Therapeutics Inc, 2022

Pipeline by Douleur Therapeutics Inc, 2022

Pipeline by Edesa Biotech Inc, 2022

Pipeline by EyeGene Inc, 2022

Pipeline by FasCure Therapeutics LLC, 2022

Pipeline by Genesen Co Ltd, 2022

Pipeline by Immunovo BV (Inactive), 2022

Pipeline by Inimmune Corp, 2022

Pipeline by Kupando GmbH, 2022

Pipeline by Lubris Biopharma, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Pattern Pharma Inc, 2022

Pipeline by Protara Therapeutics Inc, 2022

Pipeline by Revelation Biosciences Inc, 2022

Pipeline by Soin Therapeutics LLC, 2022

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022

Pipeline by Vascular Biogenics Ltd, 2022

Pipeline by Xalud Therapeutics Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/T22085E9A2D4EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T22085E9A2D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

